Fig. 10 | Scientific Reports

Fig. 10

From: Development and validation of a risk model for effective immune and stromal related signature predicting prognosis of patients with ovarian cancer

Fig. 10

Chemotherapeutic sensitivity and in vitro validation of sorafenib efficacy. (A) Box plot illustrating differences in sorafenib sensitivity between high- and low-risk groups, showing significantly increased sensitivity in the low-risk group. (B-C) Transwell invasion assays demonstrating reduced invasion capacity in SKOV3 and A2780 cells treated with 20 µM sorafenib. *, p < 0.05; **, p < 0.01; ***, p < 0.001. (D-E) Wound healing assays showing impaired migration in SKOV3 and A2780 cells treated with 20 µM sorafenib, highlighting its potential to suppress metastasis in vitro. *, p < 0.05; **, p < 0.01; ***, p < 0.001.

Back to article page